I am a
Home I AM A Search Login

Papers of the Week

2022 Sep

Ophthalmol Sci



A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.


Sugar A, Hussain M, Chamberlain W, Dana R, Kelly D P, Ta C, Irvine J, Daluvoy M, Perez V, Olson J, Jhanji V, Walts TA, Stulting R D, Waller EK, Jagirdar N
Ophthalmol Sci. 2022 Sep; 2(3):100176.
PMID: 36245754.


The purpose of the study was to evaluate, as a pilot trial, safety and tolerability of CAM-101 10% and 30% topical ophthalmic fibrinogen-depleted human platelet lysate (FD hPL) solution in patients with dry eye disease (DED) secondary to graft-versus-host disease (GvHD) after 6 weeks of treatment.